Developer docs
API playgroundTry for free, no card

Search company profiles

TechsoMed

Full company profile

uuid0000yvo

Namestring
TechsoMed
Legal namestring
Techsomed Ltd.
Websiteurl
techsomed.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

TechsoMed is a privately-held Israeli medical AI software company founded in 2015 and headquartered in Israel (with operating subsidiaries in Germany and Japan) that develops AI-powered image-guided therapy software for thermal ablation procedures used in interventional oncology. The company's flagship product is the BioTraceIO360 platform, which comprises two FDA-cleared software products—BioTraceIO Vision and BioTraceIO Precision—and delivers a full Plan-Monitor-Assess ablation workflow that unifies CT, MRI, and ultrasound imaging data using generative AI, computer vision, and predictive analytics. The platform holds the world's first FDA De Novo clearance for ultrasound-based tissue response prediction in liver tumor ablation (January 2024) and has expanded to kidney ablation via a 510(k) clearance in September 2025.

The underlying technology compresses thousands of imaging frames into a single actionable interface with risk-aware 3D models, providing real-time tumor margin visualization, multi-modal image registration, and post-ablation tissue response predictions. BioTraceIO360 is positioned as a vendor-agnostic, OEM-style software layer that integrates with major ultrasound systems (GE HealthCare Logiq) and ablation hardware (Medtronic Emprint microwave ablation system). The company operates an IGT Roadmap initiative to extend the platform into radiation therapy, cryoablation, cardiovascular ablation, and pain management.

TechsoMed generates revenue primarily through enterprise software licensing (subscription/recurring and one-time license models) to large hospital systems and academic medical centers, sold through direct field sales, channel partnerships (most notably Medtronic as of October 2025), and field evaluation programs with imaging OEMs. Primary end-users are interventional radiologists and oncology care centers performing liver, kidney, and other solid tumor ablation procedures, with secondary exposure to urology/oncology programs treating kidney cancer. Backed by approximately $9.6M in disclosed funding across a 2019 round and a 2021 $7M Series B led by Axil Capital, the company employs 11-50 people and is led by founder and CEO Yossi Abu.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRehovot, Israel
HQ citystring
Rehovot
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
image-guided ablation software, interventional oncology software, tissue response prediction, AI medical imaging, FDA-cleared ablation platform
Industry2 codes
1Interventional Radiology & Image-Guided Therapy Systems
CodeHLAHABAGPrimaryYes
2Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim)
CodeHLAHABAHPrimaryNo
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Image-Guided Therapy Software
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1BioTraceIO Software Licensing
TypeSubscription Recurring
Description

SaaS/software licensing model for FDA-cleared medical device software. BioTraceIO360 platform comprising BioTraceIO Vision and BioTraceIO Precision products sold to healthcare institutions for use in ablation procedures. Revenue likely generated through software licenses (subscription or perpetual) to hospitals and interventional radiology departments.

techsomed.com
2Enterprise Software Deployment
TypeOne Time License
Description

Direct enterprise sales of software solutions to large hospital systems and academic medical centers. Includes implementation, training, and support services bundled with software licenses.

techsomed.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1BioTrace
Description

AI-powered image-guided ablation therapy platform that provides real-time visualization, treatment planning, and tissue response prediction for minimally invasive procedures. Includes BioTraceIO Vision and BioTraceIO Precision software products.

techsomed.com
+2 more records
Core offering1 text field

TechsoMed develops and sells BioTraceIO360, an FDA-cleared AI-powered image-guided ablation therapy software platform for minimally invasive cancer treatment. The software unifies CT, MRI, and ultrasound imaging into a full-cycle ablation workflow covering pre-procedure planning, intra-procedure guidance with quantitative feedback, and post-treatment tissue response prediction for liver and kidney tumor ablation procedures performed by interventional radiologists.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Addresses failure rate where more than half of ablation treatments are unable to completely eliminate cancerous tissue
+1 more record
Product overview1 text field

TechsoMed offers a unified platform-plus-modules architecture centered on the BioTraceIO360 system, which comprises two FDA-cleared software products: BioTraceIO Vision and BioTraceIO Precision. These modules work together to provide full-cycle ablation management covering Plan, Monitor, and Assess phases. The platform integrates with standard medical imaging modalities (CT, MRI, ultrasound) and uses generative AI to deliver real-time tissue response prediction, tumor margin visualization, and treatment verification. The company also operates an IGT Roadmap initiative expanding AI capabilities into additional therapy verticals including radiation therapy, cryoablation, and cardiovascular ablation.

Product and service1 record
1BioTraceIO360
CategoryImage-Guided Therapy Software
Description

FDA-cleared AI-powered image-guided ablation therapy platform comprising BioTraceIO Vision and BioTraceIO Precision software products. Provides full-cycle ablation management (Plan, Monitor, Assess) for interventional radiologists treating liver and kidney tumors, including tissue response prediction, real-time tumor margin visualization, multi-modal image registration, and post-treatment verification.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Medtronic
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-10-16
Description

Pilot collaboration to develop an integrated solution for image-guided ablation therapy combining Techsomed's BioTraceIO360 software with Medtronic's Emprint microwave ablation system. The partnership aims to improve real-time visualization and treatment precision in minimally invasive therapies, establishing new standards in ablation treatment. Medtronic provides industry-leading ablation technology and in-vivo therapy datasets.

2Hadassah Medical Center / Hadasit
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-03
Description

Strategic pilot collaboration to advance next-generation minimally invasive image-guided therapies targeting tumor radiotherapy. The partnership leverages Hadassah's extensive imaging datasets and clinical expertise to direct and implement BioTrace's treatment planning, validation, real-time visualization, predictive modeling, and in-procedure decision support into radiotherapy workflows. Aims to position Hadassah as a Center of Excellence for AI-driven image-guided therapy.

3GE HealthCare
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-06-01
Description

Field evaluation of BioTrace.IO 360 using GE HealthCare's Logiq ultrasound systems at top US clinical sites. The evaluation assessed the integration of Techsomed's image-guided ablation therapy software with GE's ultrasound imaging platforms.

4Fraunhofer Mevis
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-01
Description

Partnership for opening Techsomed's German subsidiary in Bremen with Fraunhofer Mevis to accelerate end-to-end solutions for image-guided thermal ablation therapy. Focuses on research and development of AI-powered solutions for IGT.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TechsoMed

Image-Guided Therapy Softwaretechsomed.com

What TechsoMed does

TechsoMed is a privately-held Israeli medical AI software company founded in 2015 and headquartered in Israel (with operating subsidiaries in Germany and Japan) that develops AI-powered image-guided therapy software for thermal ablation procedures used in interventional oncology. The company's flagship product is the BioTraceIO360 platform, which comprises two FDA-cleared software products—BioTraceIO Vision and BioTraceIO Precision—and delivers a full Plan-Monitor-Assess ablation workflow that unifies CT, MRI, and ultrasound imaging data using generative AI, computer vision, and predictive analytics. The platform holds the world's first FDA De Novo clearance for ultrasound-based tissue response prediction in liver tumor ablation (January 2024) and has expanded to kidney ablation via a 510(k) clearance in September 2025.

The underlying technology compresses thousands of imaging frames into a single actionable interface with risk-aware 3D models, providing real-time tumor margin visualization, multi-modal image registration, and post-ablation tissue response predictions. BioTraceIO360 is positioned as a vendor-agnostic, OEM-style software layer that integrates with major ultrasound systems (GE HealthCare Logiq) and ablation hardware (Medtronic Emprint microwave ablation system). The company operates an IGT Roadmap initiative to extend the platform into radiation therapy, cryoablation, cardiovascular ablation, and pain management.

TechsoMed generates revenue primarily through enterprise software licensing (subscription/recurring and one-time license models) to large hospital systems and academic medical centers, sold through direct field sales, channel partnerships (most notably Medtronic as of October 2025), and field evaluation programs with imaging OEMs. Primary end-users are interventional radiologists and oncology care centers performing liver, kidney, and other solid tumor ablation procedures, with secondary exposure to urology/oncology programs treating kidney cancer. Backed by approximately $9.6M in disclosed funding across a 2019 round and a 2021 $7M Series B led by Axil Capital, the company employs 11-50 people and is led by founder and CEO Yossi Abu.

TechsoMed firmographics

Firmographics
Name
TechsoMed
Legal name
Techsomed Ltd.
Website
https://techsomed.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

TechsoMed industry classification

Industry
Product category
Image-Guided Therapy Software
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG)
akta.pro secondary industry
Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim) (HLAHABAH)

Keywords

  • Image-guided ablation software
  • Interventional oncology software
  • Tissue response prediction
  • AI medical imaging
  • FDA-cleared ablation platform

Where TechsoMed is headquartered

Location

Headquarters

HQ city
Rehovot
HQ country
Israel
HQ region
Middle East

Offices3 records

Markets served

TechsoMed business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. BioTraceIO Software Licensing: SaaS/software licensing model for FDA-cleared medical device software. BioTraceIO360 platform comprising BioTraceIO Vision and BioTraceIO Precision products sold to healthcare institutions for use in ablation procedures. Revenue likely generated through software licenses (subscription or perpetual) to hospitals and interventional radiology departments.
  2. Enterprise Software Deployment: Direct enterprise sales of software solutions to large hospital systems and academic medical centers. Includes implementation, training, and support services bundled with software licenses.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

TechsoMed product offering

Product offering

Core offering

TechsoMed develops and sells BioTraceIO360, an FDA-cleared AI-powered image-guided ablation therapy software platform for minimally invasive cancer treatment. The software unifies CT, MRI, and ultrasound imaging into a full-cycle ablation workflow covering pre-procedure planning, intra-procedure guidance with quantitative feedback, and post-treatment tissue response prediction for liver and kidney tumor ablation procedures performed by interventional radiologists.

Product overview

TechsoMed offers a unified platform-plus-modules architecture centered on the BioTraceIO360 system, which comprises two FDA-cleared software products: BioTraceIO Vision and BioTraceIO Precision. These modules work together to provide full-cycle ablation management covering Plan, Monitor, and Assess phases. The platform integrates with standard medical imaging modalities (CT, MRI, ultrasound) and uses generative AI to deliver real-time tissue response prediction, tumor margin visualization, and treatment verification. The company also operates an IGT Roadmap initiative expanding AI capabilities into additional therapy verticals including radiation therapy, cryoablation, and cardiovascular ablation.

Differentiator

Problem solved

Functional benefit

Brands

  • BioTrace: AI-powered image-guided ablation therapy platform that provides real-time visualization, treatment planning, and tissue response prediction for minimally invasive procedures. Includes BioTraceIO Vision and BioTraceIO Precision software products.
  • BioTraceIO360
  • IGT Roadmap

Products and services

  • BioTraceIO360 FDA-cleared AI-powered image-guided ablation therapy platform comprising BioTraceIO Vision and BioTraceIO Precision software products. Provides full-cycle ablation management (Plan, Monitor, Assess) for interventional radiologists treating liver and kidney tumors, including tissue response prediction, real-time tumor margin visualization, multi-modal image registration, and post-treatment verification.

Quantifiable outcome

  • Addresses failure rate where more than half of ablation treatments are unable to completely eliminate cancerous tissue
  • +1 more outcomes

Companies that use TechsoMed

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles1 record

TechsoMed technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature8 records

TechsoMed partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship and core.

  • MedtronicflagshipStrategic or Co-development Partner · 16 October 2025Pilot collaboration to develop an integrated solution for image-guided ablation therapy combining Techsomed's BioTraceIO360 software with Medtronic's Emprint microwave ablation system. The partnership aims to improve real-time visualization and treatment precision in minimally invasive therapies, establishing new standards in ablation treatment. Medtronic provides industry-leading ablation technology and in-vivo therapy datasets.
  • Hadassah Medical Center / HadasitcoreStrategic or Co-development Partner · 3 July 2025Strategic pilot collaboration to advance next-generation minimally invasive image-guided therapies targeting tumor radiotherapy. The partnership leverages Hadassah's extensive imaging datasets and clinical expertise to direct and implement BioTrace's treatment planning, validation, real-time visualization, predictive modeling, and in-procedure decision support into radiotherapy workflows. Aims to position Hadassah as a Center of Excellence for AI-driven image-guided therapy.
  • GE HealthCarecoreTechnology or Integration · 1 June 2023Field evaluation of BioTrace.IO 360 using GE HealthCare's Logiq ultrasound systems at top US clinical sites. The evaluation assessed the integration of Techsomed's image-guided ablation therapy software with GE's ultrasound imaging platforms.
  • Fraunhofer MeviscoreStrategic or Co-development Partner · 1 June 2023Partnership for opening Techsomed's German subsidiary in Bremen with Fraunhofer Mevis to accelerate end-to-end solutions for image-guided thermal ablation therapy. Focuses on research and development of AI-powered solutions for IGT.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

TechsoMed competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

TechsoMed social profiles

Digital presence

TechsoMed compliance and trust

Trust signal

Compliance1 record

TechsoMed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TechsoMed leadership team

Management profile

Number of profiles

Profiles12 records

TechsoMed subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

TechsoMed funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TechsoMed M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TechsoMed

What does TechsoMed do?

TechsoMed develops and sells BioTraceIO360, an FDA-cleared AI-powered image-guided ablation therapy software platform for minimally invasive cancer treatment. The software unifies CT, MRI, and ultrasound imaging into a full-cycle ablation workflow covering pre-procedure planning, intra-procedure guidance with quantitative feedback, and post-treatment tissue response prediction for liver and kidney tumor ablation procedures performed by interventional radiologists.

Is TechsoMed a public or private company?

TechsoMed is a private company. It is classified as venture growth investor backed and is currently operating.

When was TechsoMed founded?

TechsoMed was founded in 2015. It employs 11 to 50 people.

Where is TechsoMed based?

TechsoMed is headquartered in Rehovot, Israel, in the Middle East region.

How does TechsoMed make money?

Two revenue lines are on record. BioTraceIO Software Licensing is the primary driver. The others are enterprise Software Deployment.

Does TechsoMed have an API?

No public API is recorded for TechsoMed.

What industry is TechsoMed in?

TechsoMed's product category is Image-Guided Therapy Software. Its primary akta.pro industry code is HLAHABAG, Interventional Radiology & Image-Guided Therapy Systems, with a secondary code of HLAHABAH, Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireTechsomed and Medtronic to Collaborate on Image Guided Ablation TherapyTechsomed Ltd. and Medtronic have announced a pilot collaboration to combine Techsomed's BioTraceIO360™ AI-powered image guidance software with Medtronic's Emprint™ microwave ablation system for minimally invasive tumor treatment. The integrated solution aims to address challenges in ablation therapy such as limited intra-procedural visibility and non-integrated technologies, potentially reducing the need for repeat interventions. The partnership seeks to provide interventional radiologists with advanced real-time visualization, predictive margin control, and dynamic treatment planning capabilities.PR NewswireTechsomed Announces FDA Clearance for Ablation Treatment Planning and Confirmation SoftwareTechsomed Ltd. announced that it received 510(k) clearance from the U.S. Food and Drug Administration for VisAble.IO, a software tool designed to assist physicians in planning and confirming liver ablation procedures. This regulatory approval is part of Techsomed's broader BioTrace platform, which utilizes AI-based image guidance to improve treatment precision and reduce recurrence risks in ablation therapy.PR NewswireTechsoMed Ltd. announces the opening of a new German Subsidiary, as a strategic collaboration with Research Institute Fraunhofer MEVIS, to accelerate End-to-End Solution for Image-Guided Tumor AblatioTechsoMed Ltd. announced the establishment of a new German subsidiary, TechsoMed GmbH, in collaboration with the Fraunhofer Institute for Digital Medicine MEVIS to advance its BioTraceIO 360 software technology. The partnership involves an exclusive license of Fraunhofer MEVIS's SAFIR technology to enhance real-time image-guided tumor ablation procedures. This strategic move aims to improve treatment accuracy and safety while positioning minimally invasive thermal ablation as a first-line therapy option.FinSMEsTechsoMed Raises $7M in Series B FinancingTechsoMed, an Israeli AI-based tissue imaging company, closed a $7M Series B led by Axil Capital. The BioTrace platform targets liver tumor ablation, with FDA approval anticipated in 2022. The company is also developing cardiac and pain ablation applications.PR NewswireTechsoMed Raises $7 Million Series B financing led by Axil CapitalTechsoMed, an Israeli medical imaging software company, has closed a US$7 million Series B equity financing round led by Axil Capital with participation from Yongjin Capital, Cobro Ventures, Magna Capital Partners, Radianx Capital, and existing investors Johnson & Johnson Innovation – JJDC, Inc. and NextLeap Ventures. The company develops the BioTrace platform, an AI-powered technology enabling real-time visualization of tissue viability during thermal ablation procedures, with FDA De Novo regulatory approval for liver tumor ablation targeted for 2022. The funding will support scaling the technology and company operations, with investors representing diverse markets including the U.S., Japan, China, and the EU.FinSMEsTechsomed Raises $2.6M in FundingTechsomed, an Israeli developer of ultrasound-based thermal ablation monitoring, raised $2.6M led by Johnson & Johnson Innovation. The funds will support development toward FDA, PMDA, and CE regulatory approval. The company's BioTrace system uses AI to predict post-treatment ablation morphology in real time.PR NewswireTechsomed Secures $2.6M for Groundbreaking Real-time Predictive Imaging System for Thermal AblationIsraeli biotech company Techsomed has secured $2.6 million in funding for the continued development and regulatory approval of BioTrace™, a real-time predictive imaging system for thermal ablation procedures. The financing round was led by Johnson & Johnson Innovation – JJDC, Inc., with participation from SCREEN Holdings, AMIT-Technion, NextLeap Ventures, and Axil Capital. The funding will support FDA, PMDA, and CE regulatory approvals, with Techsomed planning to open a subsidiary in Japan to target commercialization in Asian markets.